攻克低液氦超导磁体技术，「普思影医疗」获近亿元A轮融资

Core Viewpoint - Pusiying Medical aims to deliver the first batch of 3.0T low-liquid helium superconducting magnets to major domestic clients by June next year, focusing on the industrialization of its PhaseXCool® technology in MRI equipment and other fields [2][9]. Financing and Technology Development - Pusiying Medical recently completed nearly 100 million yuan in Series A financing, led by Ivy Capital, with participation from existing shareholder Neusoft Capital and Xiaoming Technology. The funds will accelerate the industrialization of low-helium siphon cooling technology [3]. - The founder, Dr. Ni Zhipeng, has a strong background in superconducting magnet research, having led significant projects in this field [3][4]. Challenges of Traditional MRI Technology - Traditional MRI technology relies on liquid helium, which is a non-renewable and scarce resource, with over 95% of China's helium imported, primarily from the US and Russia. This poses risks to high-end medical equipment manufacturing in China [4]. - The cost of liquid helium has surged from 20-30 yuan per liter to 200-300 yuan per liter, leading to operational costs for a 3.0T MRI device reaching millions, comparable to manufacturing costs [4][5]. Innovations in Low-Helium Technology - Pusiying Medical's PhaseXCool® technology reduces reliance on liquid helium by using a GM cooler as a cold source, achieving efficient heat exchange for superconducting components [5][6]. - The new superconducting magnets can operate stably below 4.2K with significantly reduced liquid helium consumption, leading to a 50% reduction in overall operational costs [6][7]. Applications and Market Potential - The low-helium technology has potential applications beyond MRI, including in MR-Linac systems for cancer treatment and high-field MRI systems for brain research, which are currently expensive due to helium costs [8]. - The global MRI equipment market is projected to grow from approximately $7.1 billion in 2024 to $10.3 billion by 2030, with the low-helium MRI market expected to expand from $2.8 billion in 2024 to $5.9 billion by 2033 [9].